cagrilintide latest research Cagri - 5mg

2: Yuan C, Demers A, Silva-Ortiz V, Hasoon JJ, Lee W, Dave K, Amirdelfan K, Burke HW, Christo PJ, Robinson CL

AOD-9604 AOD-9604 is a modified fragment of human growth hormone (hGH), originally studied by pharmaceutical company Metabolic Pharmaceuticals as a potential anti-obesity compound

When demand exceeds evidence, an unregulated marketplace frequently fills the gap

Similarly, intraperitoneal administration of 0.25 mg/kg and 0.50 mg/kg and oral administration of 2.0 mg/kg of Dihexa significantly improved performance to levels comparable with vehicle controls

As of this writing, the FDA has not yet formally published the updated Category 2 list following Secretary Kennedy's February 27, 2026 announcement

Novo Nordisk filed an NDA for the CagriSema combination in December 2025, with an FDA decision anticipated in late 2026